Citigroup
PBYI icon

Citigroup’s Puma Biotechnology PBYI Stock Holding History

Citigroup’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.9K Buy
3,422
+1,042
+44% +$6.72K ﹤0.01% 4795
2025
Q4 		$14.2K Buy
2,380
+1,521
+177% +$8.08K ﹤0.01% 4959
2025
Q3 		$4.56K Sell
859
-13,461
-94% -$57.1K ﹤0.01% 5256
2025
Q2 		$49.1K Sell
14,320
-15,147
-51% -$48.3K ﹤0.01% 4764
2025
Q1 		$87.2K Sell
29,467
-3,794
-11% -$11.9K ﹤0.01% 4672
2024
Q4 		$101K Buy
33,261
+3,213
+11% +$9.35K ﹤0.01% 4832
2024
Q3 		$76.6K Buy
30,048
+10,188
+51% +$30.8K ﹤0.01% 4881
2024
Q2 		$64.7K Sell
19,860
-110,613
-85% -$486K ﹤0.01% 4443
2024
Q1 		$692K Sell
130,473
-40,580
-24% -$219K ﹤0.01% 3322
2023
Q4 		$741K Buy
171,053
+71,286
+71% +$236K ﹤0.01% 3092
2023
Q3 		$262K Buy
+99,767
New +$340K ﹤0.01% 3508
2023
Q1 		– Sell
-26,473
Closed -$112K – 5764
2022
Q4 		$112K Buy
26,473
+25,925
+4,731% +$89.5K ﹤0.01% 3976
2022
Q3 		$1K Sell
548
-429
-44% -$1.25K ﹤0.01% 5664
2022
Q2 		$3K Sell
977
-1,107
-53% -$2.75K ﹤0.01% 5790
2022
Q1 		$6K Sell
2,084
-7,141
-77% -$18.5K ﹤0.01% 5764
2021
Q4 		$28K Buy
9,225
+3,114
+51% +$13.5K ﹤0.01% 5291
2021
Q3 		$43K Sell
6,111
-86,042
-93% -$644K ﹤0.01% 4821
2021
Q2 		$846K Sell
92,153
-83,099
-47% -$842K ﹤0.01% 3354
2021
Q1 		$1.7M Buy
175,252
+128,294
+273% +$1.43M ﹤0.01% 2602
2020
Q4 		$482K Buy
46,958
+4,984
+12% +$50.5K ﹤0.01% 4240
2020
Q3 		$423K Sell
41,974
-53,770
-56% -$548K ﹤0.01% 3997
2020
Q2 		$998K Sell
95,744
-41,700
-30% -$432K ﹤0.01% 3567
2020
Q1 		$1.16M Sell
137,444
-69,085
-33% -$671K ﹤0.01% 3015
2019
Q4 		$1.81M Sell
206,529
-16,167
-7% -$134K ﹤0.01% 3104
2019
Q3 		$2.4M Sell
222,696
-119,417
-35% -$1.29M ﹤0.01% 2664
2019
Q2 		$4.35M Buy
342,113
+304,753
+816% +$7.02M ﹤0.01% 2082
2019
Q1 		$1.45M Sell
37,360
-253,810
-87% -$7.75M ﹤0.01% 2999
2018
Q4 		$5.93M Buy
291,170
+253,253
+668% +$7.6M 0.01% 1678
2018
Q3 		$1.74M Buy
37,917
+6,522
+21% +$314K ﹤0.01% 2891
2018
Q2 		$1.86M Buy
31,395
+18,525
+144% +$1.07M ﹤0.01% 2743
2018
Q1 		$877K Sell
12,870
-55,600
-81% -$4.16M ﹤0.01% 3381
2017
Q4 		$6.77M Buy
68,470
+38,905
+132% +$4.35M 0.01% 1565
2017
Q3 		$3.54M Sell
29,565
-36,197
-55% -$3.37M ﹤0.01% 2072
2017
Q2 		$5.75M Buy
65,762
+1,846
+3% +$103K 0.01% 1587
2017
Q1 		$2.38M Sell
63,916
-142,958
-69% -$5.22M ﹤0.01% 2306
2016
Q4 		$6.35M Buy
206,874
+204,579
+8,914% +$8.85M 0.01% 1580
2016
Q3 		$154K Buy
2,295
+4
+0.2% +$202 ﹤0.01% 4877
2016
Q2 		$68K Sell
2,291
-889
-28% -$27.8K ﹤0.01% 5375
2016
Q1 		$94K Sell
3,180
-5,903
-65% -$267K ﹤0.01% 5703
2015
Q4 		$712K Sell
9,083
-2,582
-22% -$203K ﹤0.01% 3501
2015
Q3 		$879K Buy
11,665
+7,274
+166% +$688K ﹤0.01% 3211
2015
Q2 		$511K Buy
4,391
+524
+14% +$94.9K ﹤0.01% 3685
2015
Q1 		$913K Sell
3,867
-4,630
-54% -$990K ﹤0.01% 3170
2014
Q4 		$1.61M Buy
8,497
+3,877
+84% +$860K ﹤0.01% 2656
2014
Q3 		$1.1M Sell
4,620
-947
-17% -$194K ﹤0.01% 2956
2014
Q2 		$367K Sell
5,567
-2,026
-27% -$144K ﹤0.01% 3661
2014
Q1 		$791K Buy
7,593
+132
+2% +$15.5K ﹤0.01% 3069
2013
Q4 		$772K Buy
7,461
+6,669
+842% +$391K ﹤0.01% 3418
2013
Q3 		$42K Buy
+792
New +$42.7K ﹤0.01% 5409

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Citigroup's PBYI Position: Q1 2026 in Review

Citigroup increased its Puma Biotechnology (PBYI) stake by 44% in Q1 2026, buying an estimated $6.72K and bringing the position to 3,422 shares worth $21.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4795.

Citigroup first reported a position in PBYI in Q3 2013 and has held it in 49 quarters since. The position peaked at $6.77M in Q4 2017. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • Citigroup held 3,422 shares of Puma Biotechnology worth $21.9K as of Q1 2026.
  • Citigroup bought 1,042 Puma Biotechnology shares in Q1 2026, an estimated $6.72K.
  • Puma Biotechnology made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4795 holding.
  • Citigroup first reported a position in Puma Biotechnology in Q3 2013 and has held it in 49 quarters since.
  • Citigroup's Puma Biotechnology position peaked at $6.77M in Q4 2017.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.